You are here
Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Living with Cystic Fibrosis and Their Families
Now Accepting Applications for the "All in for CF" Scholarship
"At Vertex, our passion is fueled by the hope and courage of the CF
community, which is clearly reflected in each All in for CF scholar,"
"Receiving this scholarship shows how we are not letting an illness get
the best of us; it shows how we are choosing to see the positive in the
negative," said All in for CF scholar
Scholarship recipients are chosen by an independent committee of CF
community members based on an applicant's demonstrated level of
community involvement, financial need, and academic achievement, as well
as a personal essay. Applications are available here
and will be accepted until
About Cystic Fibrosis
Cystic fibrosis is a rare, life-threatening genetic disease affecting approximately 75,000 people in North America, Europe and Australia. CF is caused by a defective or missing CFTR protein resulting from mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. There are approximately 2,000 known mutations in the CFTR gene. Some of these mutations, which can be determined by a genetic test, lead to CF by creating defective or too few CFTR proteins at the cell surface. The defective or missing CFTR protein results in poor flow of salt and water into or out of the cell in a number of organs, including the lungs. This leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median predicted age of survival for a person born today with CF is 41 years, but the median age of death is 27 years.
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to our clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases.
Founded in 1989 in
Vertex in the Community
Vertex has made a 10-year,
Vertex Is All In for CF
The CF community motivates Vertex employees each and every day - to dig deeper, to do more, to explore the "what ifs," and to push the boundaries of what we know. We aim to discover and develop medicines that will treat the underlying cause of CF for the vast majority of people with the disease, and our ultimate goal is to cure it. Beyond our transformational medicines, we help people with CF lead active lives and pursue higher education, and we fund independent research and innovative patient centric programs. To learn more please visit www.vrtxallincf.com.
News Provided by Acquire Media